Healthcare Industry News: diabetes
News Release - April 5, 2017
MicroPort Orthopedics Inc. Announces Launch of its EVOLUTION(R) Revision Tibial System and EVOLUTION(R) BioFoam(R) TibiaARLINGTON, Tenn.--(Healthcare Sales & Marketing Network)--MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced the launch of the EVOLUTION® Revision Tibial System and EVOLUTION® BioFoam® Tibia.
“MicroPort Orthopedics continues to grow its product portfolio with a steady cadence of product launches,” said Aurelio Sahagun, President, MicroPort Orthopedics. “These product launches demonstrate our commitment to help improve patient outcomes by giving surgeons a broad array of choices that allow them to treat their patients. We are excited to bring the benefits of the Medial-Pivot design to a revision system.”
The Evolution Medial-Pivot Knee System is built on 17 years of clinical success1 and addresses key issues that can improve satisfaction for patients undergoing total knee replacement. The EVOLUTION® Revision Tibial System is designed to offer surgeons intra-operative flexibility to meet individual anatomic patient needs, address fixation issues caused by poor bone stock, while maintaining the proven kinematic benefits of the Medial-Pivot design. The new system was designed by expert surgeons from Europe, Asia, Canada, and the United States and features all the benefits of the EVOLUTION® Medial-Pivot design.
In addition to its EVOLUTION® Revision Tibial System, MicroPort Orthopedics also announced the launch of its EVOLUTION® BioFoam® Tibia. This launch completes the EVOLUTION® Medial-Pivot Cementless System, which consists of the EVOLUTION® porous femoral component and the new EVOLUTION® BioFoam® tibial component. This system is designed to combine the unrivaled benefits of the Medial-Pivot philosophy with the advantages of early fixation without compromising the long-term demands that are required in today’s increasingly young and more active patients.2 Building on the success of the ADVANCE® BioFoam® Tibia, which reported survivorship of 98% at two years3, the EVOLUTION® BioFoam® Tibia will further enhance the product portfolio.
“I have used the MicroPort Medial-Pivot Knee System for three years,” said Dr. Brian de Beaubien, M.D., St. John’s Providence Park Hospital in Novi, MI. “The majority of my primary knees are cementless, and I do not use screws. In my experience with the ADVANCE® and now EVOLUTION®, BioFoam® has excellent fixation. I have been following x-rays now for several years, and I don't see any radiolucencies or sclerotic lines around the keel, that would suggest movement of the component. The BioFoam® Tibia combined with the unique design of the EVOLUTION® Medial-Pivot Knee is truly different from anything else. It is my go-to knee.”
About MicroPort Orthopedics Inc.
Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/.
MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 20 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.
Some information contained in this press release contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
Sources: 1. A long term clinical outcome of the Medial Pivot Knee Arthroplasty System Macheras, George A. et al. The Knee , Volume 24 , Issue 2 , 447 - 453.
2. Global Data, 2013.
3. Waddell et al. Early radiographic and functional outcomes of a cancellous titanium-coated tibial component for total knee arthroplasty. Musculoskelet Surg. 2015 Sept; 100: 71.
All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation
Source: MicroPort Orthopedics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.